Izeltabart is a high-affinity, humanized monoclonal antibody that specifically targets ADAM9 (A Disintegrin And Metalloproteinase 9). Its primary mechanism of action is designed to inhibit the proteolytic and signaling functions of ADAM9, a protein that plays a critical role in tumor progression, metastasis, and resistance to therapy. By blocking ADAM9, Izeltabart aims to interfere with cancer cell invasion, tumor-stroma interactions, and growth factor shedding, thereby potentially suppressing tumor growth and spread. It is under investigation as a potential therapeutic agent for various solid tumors, particularly those with high ADAM9 expression.